UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission file number: 001-41598

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file ~~annual~~ annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Form 20-F ☒ Form 40-F ☐

EXHIBITS

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LakeShore Biopharma Co., Ltd

	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

Date: August 1828, 2025

Filing Compare · LakeShore Biopharma Co., Ltd.